Company targets cash flow breakeven by end of 2026 with gross margins stabilizing in the high 80% to low 90% range.
Precigen reported a 145% sequential increase in PAPZIMEOS revenue for Q2 2026, reaching $53.1 million compared to $21.6 million in Q1. The surge marks accelerated growth for the product launch, according to management commentary during the earnings call.
The company expects gross margins for PAPZIMEOS to stabilize in the high 80% to low 90% range as it works toward cash flow breakeven by the end of 2026. Prior quarter revenue had set a baseline for the product’s commercial trajectory.
No immediate market reaction was detailed in the source.